Stockscreener 앱 받기
1.665
5.60%
0.085
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Trade Recap: Is Acrivon Therapeutics Inc showing insider buying2025 Sector Review & Smart Swing Trading Alerts - baoquankhu1.vn
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Short Squeeze: Why is Ameriprise Financial Inc stock going upJuly 2025 Rallies & Weekly High Momentum Picks - baoquankhu1.vn
Winners Losers: Will Acrivon Therapeutics Inc benefit from green energy policiesShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
Activity Recap: Is Acrivon Therapeutics Inc a good ESG investmentQuarterly Earnings Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $11.67 - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
RSI Check: Is Morgan Stanley Preferred Security a stock for growth or value investors2025 Fundamental Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Sectors Review: What chart patterns are forming on Acrivon Therapeutics IncTrade Entry Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Bolsamania
CEO Change: Does Vinci Partners Investments Ltd stock benefit from AI growthMarket Volume Report & Advanced Technical Signal Analysis - baoquankhu1.vn
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com Nigeria
Dow Update: Can Acrivon Therapeutics Inc beat the S P 5002025 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Endometrial cancer trial ACR-368 to be featured at European oncology event - Stock Titan
Acrivon Therapeutics Announces Late-Breaking Oral - GlobeNewswire
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), RegenXBio (RGNX) and Nurix Therapeutics (NRIX) - The Globe and Mail
Penny Stocks To Watch In January 2026 - Yahoo Finance
Insider Spends US$82k Buying More Shares In Acrivon Therapeutics - simplywall.st
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance
Tech Rally: Can Acrivon Therapeutics Inc beat the S P 500Earnings Recap Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Price Action: Can Acrivon Therapeutics Inc ride the EV waveDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares By Investing.com - Investing.com South Africa
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares - Investing.com
Top Brass Doubles Down on Acrivon With Bold Insider Buying Spree - TipRanks
Volume Report: Is BMLPRJs ROE strong enoughEarnings Risk Report & Risk Managed Investment Signals - baoquankhu1.vn
Insider Buying: Adam Levy Acquires Shares of Acrivon Therapeutics Inc (ACRV) - GuruFocus
Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Purchases 49,000 Shares - MarketBeat
Aug Decliners: Can Acrivon Therapeutics Inc ride the EV waveCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Top Acrivon Executive Makes Bold Insider Move That Signals Growing Confidence - TipRanks
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com Nigeria
Insider Buying: Eric Devroe Acquires 10,000 Shares of Acrivon Th - GuruFocus
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock - MarketBeat
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - The Globe and Mail
Movement Recap: What risks investors should watch in Acrivon Therapeutics Inc stockMarket Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Growth Value: Can Acrivon Therapeutics Inc expand into new marketsJuly 2025 Momentum & Entry Point Confirmation Signals - baoquankhu1.vn
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data By Investing.com - Investing.com South Africa
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com Australia
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Nigeria
0.95%
0.92%
자본화:
|
볼륨(24시간):